rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-575-581rsp-3652Research ArticleПЕРЕДОВАЯFRONTIERSЛимфопролиферативные опухоли при ревматических болезняхLymphoproliferative tumors in rheumatic diseaseshttps://orcid.org/0000-0001-8428-1281ГородецкийВ. Р.GorodetskiyV. R.

115522, Москва, Каширское шоссе, 34а

Vadim R. Gorodetskiy 

115522, Moscow, Kashirskoye Highway, 34A

gorodetskiyblood@mail.ruhttps://orcid.org/0000-0002-0995-1801ПоддубнаяИ. В.PoddubnayaI. V.

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Irina V. Poddubnaya 

125993, Moscow, Barrikadnaya str., 2/1, building 1

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

119991, Москва, ул. Трубецкая, 8, стр. 2

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A

119991, Moscow, Trubetskaya str., 8, building 2

 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» ; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology ; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202426122024626575581Copyright © Городецкий В.Р., Поддубная И.В., Насонов Е.Л., 20242024Городецкий В.Р., Поддубная И.В., Насонов Е.Л.Gorodetskiy V.R., Poddubnaya I.V., Nasonov E.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3652

Развитие лимфоидных опухолей у пациентов с ревматическими заболеваниями может значительно ухудшать качество жизни и негативно влиять на прогноз. В статье приведены современные данные о взаимосвязи лимфоидных опухолей с ревматическими заболеваниями. Даны практические рекомендации по дифференциальной диагностике T‑клеточного лейкоза из больших гранулированных лимфоцитов у пациентов с ревматоидным артритом с синдромом Фелти. Приведены результаты исследования патогенеза и биологических прогностических предикторов диффузной В‑клеточной крупноклеточной лимфомы у пациентов с ревматическими заболеваниями. Изучение патогенеза развития лимфопролиферативных опухолей у пациентов с ревматическими заболеваниями, несомненно, будет способствовать как более глубокому пониманию фундаментальных механизмов развития спорадических лимфопролиферативных опухолей и аутоиммунных заболеваний, так и разработке инноваций в лечении этих болезней.

The development of lymphoid tumors in patients with rheumatic diseases can significantly worsen the quality of life and negatively affect the prognosis. The article presents modern data on the relationship between lymphoid tumors and rheumatic diseases. Practical differential diagnosis guidelines of T cell large granular lymphocytic leukemia in patients with rheumatoid arthritis and Felty’s syndrome are given. The results of the study of pathogenesis and biological predictors of diffuse large B cell lymphoma in patients with rheumatic diseases are presented. This study of the lymphoproliferative tumor pathogenesis in patients with rheumatic diseases sheds light on the mechanisms underlying the development of sporadic lymphoproliferative tumors and autoimmune diseases, as well as on the progress in the treatment of these diseases.

лимфоидная опухольревматическое заболеваниеT клеточный лейкоз из больших гранулированных лимфоцитовсиндром Фелтидиффузная В клеточная крупноклеточная лимфомапатогенезlymphoid tumorrheumatic diseaseT cell large granular lymphocytic leukemiaFelty’s syndromediffuse large B cell lymphomapathogenesisReferencesEkström Smedby K, Vajdic CM, Falster M, Engels EA, MartínezMaza O, Turner J, et al. Autoimmune disorders and risk of nonHodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038. doi: 10.1182/blood-2007-10-119974Ekström Smedby K, Vajdic CM, Falster M, Engels EA, MartínezMaza O, Turner J, et al. Autoimmune disorders and risk of nonHodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038. doi: 10.1182/blood-2007-10-119974Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069-2077. doi: 10.1158/1055-9965.EPI-06-0300Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069-2077. doi: 10.1158/1055-9965.EPI-06-0300Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60. doi: 10.1093/jnci/djj004Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60. doi: 10.1093/jnci/djj004Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 2001;27(4):750-756. doi: 10.1006/bcmd.2001.0442Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 2001;27(4):750-756. doi: 10.1006/bcmd.2001.0442Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006;18(2):129-134. doi: 10.1097/01.bor.0000209423.39033.94Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006;18(2):129-134. doi: 10.1097/01.bor.0000209423.39033.94Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study. Ann Oncol. 2014;25(10):2025-2030. doi: 10.1093/annonc/mdu365Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study. Ann Oncol. 2014;25(10):2025-2030. doi: 10.1093/annonc/mdu365Kitamura W, Asada N, Tabata T, Shibata R, Nishi T, Kato Y, et al. Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. J Clin Exp Hematop. 2022;62(1):35-40. doi: 10.3960/jslrt.21010Kitamura W, Asada N, Tabata T, Shibata R, Nishi T, Kato Y, et al. Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. J Clin Exp Hematop. 2022;62(1):35-40. doi: 10.3960/jslrt.21010Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, et al. Large granular lymphocytic leukemia – A retrospective study of 319 cases. Am J Hematol. 2021;96(7):772-780. doi: 10.1002/ajh.26183Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, et al. Large granular lymphocytic leukemia – A retrospective study of 319 cases. Am J Hematol. 2021;96(7):772-780. doi: 10.1002/ajh.26183Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: A report on 229 cases. Haematologica. 2010;95(9):1534-1541. doi: 10.3324/haematol.2009.018481Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: A report on 229 cases. Haematologica. 2010;95(9):1534-1541. doi: 10.3324/haematol.2009.018481Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. Leuk Res. 2020;90:106299. doi: 10.1016/j.leukres.2020.106299Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. Leuk Res. 2020;90:106299. doi: 10.1016/j.leukres.2020.106299Schwaneck EC, Renner R, Junker L, Einsele H, Gadeholt O, Geissinger E, et al. Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis: A comprehensive analysis of 529 patients. Arthritis Rheumatol. 2018;70(12):1914-1922. doi: 10.1002/art.40654Schwaneck EC, Renner R, Junker L, Einsele H, Gadeholt O, Geissinger E, et al. Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis: A comprehensive analysis of 529 patients. Arthritis Rheumatol. 2018;70(12):1914-1922. doi: 10.1002/art.40654Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016;139(Pt 5):1348-1360. doi: 10.1093/brain/aww024Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016;139(Pt 5):1348-1360. doi: 10.1093/brain/aww024Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016-2024. doi: 10.1093/rheumatology/keab716Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016-2024. doi: 10.1093/rheumatology/keab716Quintanilla-Martinez L, Fend F. Turning up the heat on salivary gland MALT lymphoma. Blood. 2022;139(14):2094-2096. doi: 10.1182/blood.2021012624Quintanilla-Martinez L, Fend F. Turning up the heat on salivary gland MALT lymphoma. Blood. 2022;139(14):2094-2096. doi: 10.1182/blood.2021012624Насонов ЕЛ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: перспективы. Терапевтический архив. 2022;94(5):605-609. doi: 10.26442/00403660.2022.05.201501Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii arkhiv. 2022;94(5):605-609 (In Russ.). doi: 10.26442/00403660.2022.05.201501Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer. 1987;60(12):2971-2978. doi: 10.1002/1097-0142(19871215)60:12<2971::aid-cncr2820601220>3.0.co;2-oSemenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer. 1987;60(12):2971-2978. doi: 10.1002/1097-0142(19871215)60:12<2971::aid-cncr2820601220>3.0.co;2-oSemenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood. 1997;89(1):256-260.Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood. 1997;89(1):256-260.Cheon H, Dziewulska KH, Moosic KB, Olson KC, Gru AA, Feith DJ, et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr Hematol Malig Rep. 2020;15(2):103-112. doi: 10.1007/s11899-020-00565-6Cheon H, Dziewulska KH, Moosic KB, Olson KC, Gru AA, Feith DJ, et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr Hematol Malig Rep. 2020;15(2):103-112. doi: 10.1007/s11899-020-00565-6Narváez J, Domingo-Domenech E, Gómez-Vaquero C, LópezVives L, Estrada P, Aparicio M, et al. Biological agents in the management of Felty’s syndrome: A systematic review. Semin Arthritis Rheum. 2012;41(5):658-668. doi: 10.1016/j.semarthrit.2011.08.008Narváez J, Domingo-Domenech E, Gómez-Vaquero C, LópezVives L, Estrada P, Aparicio M, et al. Biological agents in the management of Felty’s syndrome: A systematic review. Semin Arthritis Rheum. 2012;41(5):658-668. doi: 10.1016/j.semarthrit.2011.08.008Shipley E, Héraud A, Hennette A, Vernhes JP. Efficacy of rituximab in Felty’s syndrome. Joint Bone Spine. 2008;75(5):621-622. doi: 10.1016/j.jbspin.2008.02.018Shipley E, Héraud A, Hennette A, Vernhes JP. Efficacy of rituximab in Felty’s syndrome. Joint Bone Spine. 2008;75(5):621-622. doi: 10.1016/j.jbspin.2008.02.018Wang CR, Chiu YC, Chen YC. Successful treatment of refractory neutropenia in Felty’s syndrome with rituximab. Scand J Rheumatol. 2018;47(4):340-341. doi: 10.1080/03009742.2017.1334816Wang CR, Chiu YC, Chen YC. Successful treatment of refractory neutropenia in Felty’s syndrome with rituximab. Scand J Rheumatol. 2018;47(4):340-341. doi: 10.1080/03009742.2017.1334816Proc K, Madej M, Wiland P, Sebastian A. Biological treatment in Felty’s syndrome with profound neutropenia. Reumatologia. 2023;61(3):213-218. doi: 10.5114/reum/167472Proc K, Madej M, Wiland P, Sebastian A. Biological treatment in Felty’s syndrome with profound neutropenia. Reumatologia. 2023;61(3):213-218. doi: 10.5114/reum/167472Gorodetskiy VR, Sidorova YV, Kupryshina NA, Vasilyev VI, Probatova NA, Ryzhikova NV, et al. Analysis of a single-institution cohort of patients with Felty’s syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. Rheumatol Int. 2021;41(1):147-156. doi: 10.1007/s00296-020-04757-4Gorodetskiy VR, Sidorova YV, Kupryshina NA, Vasilyev VI, Probatova NA, Ryzhikova NV, et al. Analysis of a single-institution cohort of patients with Felty’s syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. Rheumatol Int. 2021;41(1):147-156. doi: 10.1007/s00296-020-04757-4Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20(5):245-266. doi: 10.1016/j.blre.2006.01.003Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20(5):245-266. doi: 10.1016/j.blre.2006.01.003Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362. doi: 10.1172/JCI9940Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362. doi: 10.1172/JCI9940Shahmarvand N, Nagy A, Shahryari J, Ohgami RS. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci. 2018;109(4):926-933. doi: 10.1111/cas.13525Shahmarvand N, Nagy A, Shahryari J, Ohgami RS. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci. 2018;109(4):926-933. doi: 10.1111/cas.13525Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013;27(7):1598-1600. doi: 10.1038/leu.2012.350Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013;27(7):1598-1600. doi: 10.1038/leu.2012.350Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048- 3057. doi: 10.1182/blood-2012-06-435297Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048- 3057. doi: 10.1182/blood-2012-06-435297Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmä- ki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905- 1913. doi: 10.1056/NEJMoa1114885Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmä- ki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905- 1913. doi: 10.1056/NEJMoa1114885Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, Chen D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018;73:74-81. doi: 10.1016/j.humpath.2017.12.014Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, Chen D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018;73:74-81. doi: 10.1016/j.humpath.2017.12.014Wegscheider C, Ferincz V, Schöls K, Maieron A. Felty’s syndrome. Front Med (Lausanne). 2023;10:1238405. doi: 10.3389/fmed.2023.1238405Wegscheider C, Ferincz V, Schöls K, Maieron A. Felty’s syndrome. Front Med (Lausanne). 2023;10:1238405. doi: 10.3389/fmed.2023.1238405Gorodetskiy V, Sidorova Y, Biderman B, Kupryshina N, Ryzhikova N, Sudarikov A. STAT3 mutations in “gray-zone” cases of T-cell large granular lymphocytic leukemia associated with autoimmune rheumatic diseases. Front Med (Lausanne). 2022;9:1000265. doi: 10.3389/fmed.2022.1000265Gorodetskiy V, Sidorova Y, Biderman B, Kupryshina N, Ryzhikova N, Sudarikov A. STAT3 mutations in “gray-zone” cases of T-cell large granular lymphocytic leukemia associated with autoimmune rheumatic diseases. Front Med (Lausanne). 2022;9:1000265. doi: 10.3389/fmed.2022.1000265Armstrong RD, Fernandes L, Gibson T, Kauffmann EA. Felty’s syndrome presenting without arthritis. Br Med J (Clin Res Ed). 1983;287(6405):1620. doi: 10.1136/bmj.287.6405.1620Armstrong RD, Fernandes L, Gibson T, Kauffmann EA. Felty’s syndrome presenting without arthritis. Br Med J (Clin Res Ed). 1983;287(6405):1620. doi: 10.1136/bmj.287.6405.1620Bradley JD, Pinals RS. Felty’s syndrome presenting without arthritis. Clin Exp Rheumatol. 1983;1(3):257-259.Bradley JD, Pinals RS. Felty’s syndrome presenting without arthritis. Clin Exp Rheumatol. 1983;1(3):257-259.Fitzgerald P, O’Brien AA, Daly PA. Felty’s syndrome presenting with severe extra-articular features in the absence of clinical rheumatoid arthritis. Ir Med J. 1984;77(12):397-398.Fitzgerald P, O’Brien AA, Daly PA. Felty’s syndrome presenting with severe extra-articular features in the absence of clinical rheumatoid arthritis. Ir Med J. 1984;77(12):397-398.Rozin A, Hoffman R, Hayek T, Balbir-Gurman A. Felty’s syndrome without rheumatoid arthritis? Clin Rheumatol. 2013;32(5):701-704. doi: 10.1007/s10067-012-2157-3Rozin A, Hoffman R, Hayek T, Balbir-Gurman A. Felty’s syndrome without rheumatoid arthritis? Clin Rheumatol. 2013;32(5):701-704. doi: 10.1007/s10067-012-2157-3Marchand T, Lamy T. The complex relationship between large granular lymphocyte leukemia and rheumatic disease. Expert Rev Clin Immunol. 2024;20(3):291-303. doi: 10.1080/1744666X.2023.2292758Marchand T, Lamy T. The complex relationship between large granular lymphocyte leukemia and rheumatic disease. Expert Rev Clin Immunol. 2024;20(3):291-303. doi: 10.1080/1744666X.2023.2292758Moosic KB, Ananth K, Andrade F, Feith DJ, Darrah E, Loughran TP Jr. Intersection between large granular lymphocyte leukemia and rheumatoid arthritis. Front Oncol. 2022;12:869205. doi: 10.3389/fonc.2022.869205Moosic KB, Ananth K, Andrade F, Feith DJ, Darrah E, Loughran TP Jr. Intersection between large granular lymphocyte leukemia and rheumatoid arthritis. Front Oncol. 2022;12:869205. doi: 10.3389/fonc.2022.869205Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 2010;468(7322):447-451. doi: 10.1038/nature09518Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 2010;468(7322):447-451. doi: 10.1038/nature09518Darrah E, Andrade F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol. 2018;30(1):72-78. doi: 10.1097/BOR.0000000000000452Darrah E, Andrade F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol. 2018;30(1):72-78. doi: 10.1097/BOR.0000000000000452Romero V, Fert-Bober J, Nigrovic PA, Darrah E, Haque UJ, Lee DM, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med. 2013;5(209):209ra150. doi: 10.1126/scitranslmed.3006869Romero V, Fert-Bober J, Nigrovic PA, Darrah E, Haque UJ, Lee DM, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med. 2013;5(209):209ra150. doi: 10.1126/scitranslmed.3006869Hohlfeld R, Schulze-Koops H. Cytotoxic T cells go awry in inclusion body myositis. Brain. 2016;139(Pt 5):1312-1314. doi: 10.1093/brain/aww053Hohlfeld R, Schulze-Koops H. Cytotoxic T cells go awry in inclusion body myositis. Brain. 2016;139(Pt 5):1312-1314. doi: 10.1093/brain/aww053Поддубная ИВ, Бабичева ЛГ, Барях ЕА. Диффузная В-клеточная крупноклеточная лимфома: штрихи к эпидемиологическому портрету. Современная онкология. 2023;25(3):342- 345.Poddubnaya IV, Babicheva LG, Bariakh EA. Diffuse large B-cell lymphoma: Strokes to the epidemiological portrait. A review. Journal of Modern Oncology. 2023;25(3):342-345 (In Russ.). doi: 10.26442/18151434.2023.3.202402Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005:260-266. doi: 10.1182/asheducation-2005.1.260Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005:260-266. doi: 10.1182/asheducation-2005.1.260Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): A clinicopathologic study of 24 Japanese cases. Int J Surg Pathol. 2006;14(1):43-48. doi: 10.1177/106689690601400108Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): A clinicopathologic study of 24 Japanese cases. Int J Surg Pathol. 2006;14(1):43-48. doi: 10.1177/106689690601400108Kojima M, Tsukamoto N, Yokohama A, Suzuki Y, Shimizu K, Nishikawa M, et al. B-cell lymphoma associated with Sjögren’s syndrome among Japanese patients: A clinicopathologic and immunohistochemical study of 15 cases. J Clin Exp Hematop. 2009;49(2):89-95. doi: 10.3960/jslrt.49.89Kojima M, Tsukamoto N, Yokohama A, Suzuki Y, Shimizu K, Nishikawa M, et al. B-cell lymphoma associated with Sjögren’s syndrome among Japanese patients: A clinicopathologic and immunohistochemical study of 15 cases. J Clin Exp Hematop. 2009;49(2):89-95. doi: 10.3960/jslrt.49.89Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20-28. doi: 10.1111/ejh.12116Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20-28. doi: 10.1111/ejh.12116Gorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi: 10.1007/s00296-019-04470-xGorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi: 10.1007/s00296-019-04470-xKiesewetter B, Lamm W, Dolak W, Lukas J, Mayerhoefer ME, Weber M, et al. Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019;186(3):448-459. doi: 10.1111/bjh.15953Kiesewetter B, Lamm W, Dolak W, Lukas J, Mayerhoefer ME, Weber M, et al. Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019;186(3):448-459. doi: 10.1111/bjh.15953Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207. doi: 10.1200/JCO.2010.30.0368Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207. doi: 10.1200/JCO.2010.30.0368Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594. doi: 10.1200/JCO.2007.15.9277Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594. doi: 10.1200/JCO.2007.15.9277Ichiki A, Carreras J, Miyaoka M, Kikuti YY, Jibiki T, Tazume K, et al. Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans classifier. J Clin Exp Hematop. 2017;57(2):54-63. doi: 10.3960/jslrt.17029Ichiki A, Carreras J, Miyaoka M, Kikuti YY, Jibiki T, Tazume K, et al. Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans classifier. J Clin Exp Hematop. 2017;57(2):54-63. doi: 10.3960/jslrt.17029Lu TX, Fan L, Wang L, Wu JZ, Miao KR, Liang JH, et al. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget. 2015;6(21):18374-18388. doi: 10.18632/oncotarget.4073Lu TX, Fan L, Wang L, Wu JZ, Miao KR, Liang JH, et al. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget. 2015;6(21):18374-18388. doi: 10.18632/oncotarget.4073Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688-1697. doi: 10.1038/modpathol.2017.93Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688-1697. doi: 10.1038/modpathol.2017.93Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-217. doi: 10.1111/j.1365-2559.2008.03076.xYoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-217. doi: 10.1111/j.1365-2559.2008.03076.xНасонов ЕЛ. Достижения ревматологии в XXI в. Научно-практическая ревматология. 2014;52(2):133-140.Nasonov EL. Achievements in rheumatology in the XXI century. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(2):133-140 (In Russ.). doi: 10.14412/1995-4484-2014-133-140

The authors declare that there are no conflicts of interest present.